CN107890475A - 淫羊藿提取物的制备方法与制得的提取物 - Google Patents
淫羊藿提取物的制备方法与制得的提取物 Download PDFInfo
- Publication number
- CN107890475A CN107890475A CN201711266651.5A CN201711266651A CN107890475A CN 107890475 A CN107890475 A CN 107890475A CN 201711266651 A CN201711266651 A CN 201711266651A CN 107890475 A CN107890475 A CN 107890475A
- Authority
- CN
- China
- Prior art keywords
- preparation
- shorthorned epimedium
- extract
- water
- thick paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018905 epimedium Nutrition 0.000 title claims abstract description 41
- 241000893536 Epimedium Species 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 title abstract description 45
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000011347 resin Substances 0.000 claims abstract description 13
- 229920005989 resin Polymers 0.000 claims abstract description 13
- 230000037182 bone density Effects 0.000 claims abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001016310 Epimedium grandiflorum Species 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims abstract description 9
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000196324 Embryophyta Species 0.000 claims description 20
- 229930182470 glycoside Natural products 0.000 claims description 20
- 150000002338 glycosides Chemical class 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 claims description 6
- 241000424773 Epimedium alpinum Species 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000007445 Chromatographic isolation Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 22
- 238000012360 testing method Methods 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000605 extraction Methods 0.000 abstract description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000002250 absorbent Substances 0.000 abstract description 5
- 230000002745 absorbent Effects 0.000 abstract description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 3
- 229930003944 flavone Natural products 0.000 abstract description 3
- -1 flavone compound Chemical class 0.000 abstract description 3
- 235000011949 flavones Nutrition 0.000 abstract description 3
- 238000011106 process-scale chromatography Methods 0.000 abstract description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 27
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 241000700159 Rattus Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 13
- 230000006698 induction Effects 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- TZJALUIVHRYQQB-UHFFFAOYSA-N Icarin Chemical compound C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 3
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
Description
组别 | 剂量 | n | AKP活力(金氏单位/100mL) |
正常对照 | — | 3 | 1.42±0.23 |
诱导对照 | — | 3 | 2.35±0.22** |
提取物A | 25μg/mL | 3 | 2.67±0.28** |
提取物B | 25μg/mL | 3 | 3.07±0.33** |
提取物C | 25μg/mL | 3 | 2.95±0.29** |
提取物D | 25μg/mL | 3 | 3.18±0.35** |
提取物E | 25μg/mL | 3 | 4.27±0.33** |
提取物F | 25μg/mL | 3 | 3.58±0.36** |
提取物G | 25μg/mL | 3 | 3.46±0.30** |
组别 | 剂量 | n | OD值 |
正常对照 | — | 3 | 0.136±0.007 |
诱导对照 | — | 3 | 0.240±0.019** |
提取物E | 25μg/mL | 3 | 0.436±0.011** |
组别 | 剂量 | n | AKP(金氏单位/100mL) | StrACP(U/L) |
假手术 | — | 6 | 5.90±0.92** | 7.01±0.62** |
模型 | — | 6 | 9.16±2.01 | 9.88±1.17 |
组合物 | 0.189g/kg | 6 | 7.17±0.98* | 8.07±1.11* |
组别 | 剂量 | n | BMD(g/cc) | Tb.N(1/mm) | Tb.Sp(mm) |
假手术 | — | 6 | 0.331±0.018** | 2.802±0.196** | 0.218±0.022** |
模型 | — | 6 | 0.121±0.019 | 0.876±0.188 | 1.118±0.223 |
组合物 | 0.189g/kg | 6 | 0.162±0.035* | 1.312±0.347* | 0.870±0.191* |
时间(min) | A(%) | B(%) |
0 | 30 | 70 |
30 | 45 | 55 |
化合物 | 含量(%) |
宝藿苷Ⅱ | 10.96 |
箭藿苷A | 5.18 |
淫羊藿次苷Ⅰ | 3.14 |
箭藿苷B | 9.56 |
鼠李糖基淫羊藿次苷Ⅱ | 17.49 |
宝藿苷Ⅶ | 3.52 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711266651.5A CN107890475B (zh) | 2017-12-05 | 2017-12-05 | 淫羊藿提取物的制备方法与制得的提取物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711266651.5A CN107890475B (zh) | 2017-12-05 | 2017-12-05 | 淫羊藿提取物的制备方法与制得的提取物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107890475A true CN107890475A (zh) | 2018-04-10 |
CN107890475B CN107890475B (zh) | 2020-06-30 |
Family
ID=61807011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711266651.5A Active CN107890475B (zh) | 2017-12-05 | 2017-12-05 | 淫羊藿提取物的制备方法与制得的提取物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107890475B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112877169A (zh) * | 2021-01-13 | 2021-06-01 | 重庆九葛源食品有限公司 | 一种葛根保健酒及其制备方法 |
CN113940943A (zh) * | 2021-10-18 | 2022-01-18 | 广东金骏康生物技术有限公司 | 淫羊藿次苷ⅰ的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460684A (zh) * | 2003-06-05 | 2003-12-10 | 张利民 | 淫羊藿提取物及其生产工艺 |
-
2017
- 2017-12-05 CN CN201711266651.5A patent/CN107890475B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460684A (zh) * | 2003-06-05 | 2003-12-10 | 张利民 | 淫羊藿提取物及其生产工艺 |
Non-Patent Citations (2)
Title |
---|
宋航: "《制药分离工程》", 31 August 2011, 华东理工大学出版社 * |
高明哲,等: "工业制备高效液相色谱法制备淫羊藿中的黄酮系列对照品", 《色谱》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112877169A (zh) * | 2021-01-13 | 2021-06-01 | 重庆九葛源食品有限公司 | 一种葛根保健酒及其制备方法 |
CN113940943A (zh) * | 2021-10-18 | 2022-01-18 | 广东金骏康生物技术有限公司 | 淫羊藿次苷ⅰ的用途 |
WO2023065478A1 (zh) * | 2021-10-18 | 2023-04-27 | 广东金骏康生物技术有限公司 | 淫羊藿次苷ⅰ的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN107890475B (zh) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101310751B (zh) | 一种具有益气养血作用的药物组合物的检测方法 | |
CN101332211B (zh) | 一种水蛭提取物及其制备方法与应用 | |
CN103222988A (zh) | 一种美洲大蠊提取物及其制备方法和应用 | |
CN103435580A (zh) | 灵芝酚a及其在制药和食品中的应用 | |
CN105148258A (zh) | 组合物及其应用,含有该组合物的制剂 | |
CN107890475A (zh) | 淫羊藿提取物的制备方法与制得的提取物 | |
CN102895278B (zh) | 牛蒡苷及苷元在制备抗帕金森病药物中的用途 | |
CN102488722B (zh) | 一种柴胡口服液的制备方法及其质量检测方法 | |
CN1977885B (zh) | 一种抗肝炎药物组合物 | |
CN108452009A (zh) | 一种包含叶下珠、云芝、丹参和紫草的中药组合物在制备治疗肝癌的药物中的应用 | |
CN106491680A (zh) | 一种预防或治疗老年痴呆的中药组合物及其制备方法 | |
CN111150740A (zh) | 竹节参中的降脂活性成分和降脂组合物及其应用 | |
CN103304518A (zh) | 倍半萜类化合物及其药物组合物与其在制药中的应用 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN104161859B (zh) | 一种用于治疗脾胃疾病的中药组合物及其制备方法 | |
CN103006633A (zh) | 羟基红花黄色素a在制备抗阿尔茨海默病药物中的应用 | |
CN108452008A (zh) | 一种包含叶下珠、云芝、丹参和紫草的中药组合物在制备抑制肝癌术后复发的药物中的应用 | |
CN106109536A (zh) | 用于神经退行性疾病或神经再生的中药组合物 | |
CN105521256A (zh) | 一种林蛙油平贝母软胶囊及其制备方法和用途 | |
CN105395808B (zh) | 一种用于治疗糖尿病的增效药物组合物 | |
CN105285623B (zh) | 一种具有提高免疫功能的保健饮料及其制法 | |
CN106074668B (zh) | 用于神经退行性疾病或神经再生的中药制剂 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN101011543A (zh) | 一种新的抗肿瘤药物组合物 | |
CN103263467A (zh) | 强力脑心康药物及制备方法和含量测定 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190328 Address after: 222001 Jiangning Industrial City, Lianyungang Economic and Technological Development Zone, Jiangsu Province Applicant after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Applicant after: JIANGSU KANION SUNSHINE PHARMACEUTICAL CO.,LTD. Address before: 222047 Jiangning Industrial City, Lianyungang Economic and Technological Development Zone, Jiangsu Province Applicant before: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 29, Hengjing Road, Economic and Technological Development Zone, Nanjing City, Jiangsu Province, 210000 Patentee after: JIANGSU KANION SUNSHINE PHARMACEUTICAL CO.,LTD. Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Address before: 222001 Jiangning Industrial City, Lianyungang Economic and Technological Development Zone, Jiangsu Province Patentee before: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU KANION SUNSHINE PHARMACEUTICAL CO.,LTD. |